Author, year | Study design, country, number of patients with MAFLD | Diagnosis of MAFLD, assessment methods for the severity of MAFLD | Sex-male%, the prevalence of colorectal neoplasms by sex | Main findings | Covariate adjustment(s) | NOS/AHRQ |
---|---|---|---|---|---|---|
Liu, 2022 [20] | Cross-sectional study, China, 331 | Ultrasonography, non-invasive fibrosis score | N/A | The degree of fibrosis in MAFLD is closely related to the prevalence of colorectal adenomatous polyp and high-risk adenoma. | Age, sex, and BMI | 9 |
Seo, 2021Â [31] | Cross-sectional study, Korea, 1127 | Ultrasonography, non-invasive fibrosis score | 79.6, 33.7%-male; 31.3%-female | MAFLD with advanced fibrosis was associated with an increased risk of colorectal adenoma. | Sex, smoking, and visceral fat area | 9 |
Chuan, 2020 [21] | Cross-sectional study, China, 78 | Fibro Touch, Fibro Touch | 67.9% (severe MAFLD group 73.1%, mild or moderate MAFLD group 65.4%), N/A | The prevalence of adenomas was similar when comparing patients with CAP≥295 dB/m vs. 240 dB/m ≤ CAP< 295 dB/m. | N/A | 8 |
Blackett, 2020 [20] | Cross-sectional study, the United States, 123 | Biopsy, biopsy | 49.6, 50.8%-male; 30.7%-female | The prevalence of adenomas was similar when comparing patients with no NASH versus NASH. | Age, sex, endoscopist, hyperlipidemia, diabetes, obesity, and colonoscopy indication | 9 |
Cho, 2019 [22] | Cohort study, Korea, 379 | Biopsy, biopsy | N/A | The prevalence of adenomas and advanced neoplasia was similar when comparing patients with NAFL versus NASH. | N/A | 6 |
Kim, 2019 [23] | Cross-sectional study, Korea, 2395 | Ultrasonography, non-invasive fibrosis score | 71.3% | MAFLD patients with advanced fibrosis had a significantly higher risk for colorectal adenomas than those without advanced fibrosis. | Age, sex, obesity, smoking, hypertension, DM, hyperlipidemia, and metabolic syndrome | 9 |
Kim, 2018 [24] | Cohort study, Korea, 8721 | Ultrasonography, non-invasive fibrosis score | 71.1%, 85.7 per 100,000 person-years -male; 30.3 per 100,000 person-years -female | The severity of MAFLD was not related to colorectal cancer | Age, sex, smoking status, diabetes, hypertension, GGT, HDL cholesterol, LDL cholesterol, and triglycerides | 8 |
Ahn, 2017 [32] | Cross-sectional study, Korea, 9501 | Ultrasonography, non-invasive fibrosis score | N/A | When compared to MAFLD patients with mild liver disease, the ORs for advanced colorectal neoplasia were higher for those with advanced fibrosis. | Age, sex, BMI, smoking, alcohol, aspirin use, fasting plasma glucose, first-degree family history of colorectal cancer, serum lipids, systolic blood pressure, drugs | 9 |
Piyachaturawat, 2016 [25] | Cross-sectional study, Thailand, 161 | TE-CAP, TE-CAP | N/A | The prevalence of adenomas and advanced adenomas was similar when comparing patients with fatty liver grade Severe vs. Mild to moderate. | N/A | 7 |
Lee, 2016 [26] | Cross-sectional study, Korea, 14,655 | Ultrasonography, ultrasonography | 86.3% (severe MAFLD group 93.9%, mild or moderate MAFLD group 86.3%), N/A | The prevalence of adenomas and advanced neoplasia was similar when comparing patients with fatty liver grade Severe vs. Mild to moderate. | N/A | 8 |
Yang, 2014 [27] | Cross-sectional study, China, 74 | Ultrasonography, ultrasonography | 90.5% (severe or moderate MAFLD group 90.6%, mild MAFLD group 90.5%), N/A | The prevalence of adenomas was similar when comparing patients with fatty liver grade Moderate to severe vs. Mild | N/A | 8 |
Tantau, 2014 [28] | Case-control study, Romania, 50 | Liver biopsy or abdominal ultrasounds, liver biopsy or abdominal ultrasounds | N/A | NASH is independently related to the prevalence of colorectal adenomas. | Demographic and metabolic factors | 7 |
Wong, 2011 [29] | Cross-sectional study, China, 135 | Biopsy, biopsy | 54.8%, N/A | NASH is independently related to the prevalence of colorectal adenomas and advanced neoplasia. | Demographic and metabolic factors | 9 |
Touzin, 2011Â [33] | Cohort study, the United States, 94 | Biopsy, biopsy | 62.8% (NASH 65.5%, non-NASH 61.5%), N/A | The prevalence of adenomas was similar when comparing patients with NASH vs. Non-NASH. | N/A | 6 |